Y.D. More Investments Ltd Buys 97,537 Shares of Brainsway Ltd. Sponsored ADR $BWAY

Y.D. More Investments Ltd increased its position in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) by 559.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 114,962 shares of the company’s stock after purchasing an additional 97,537 shares during the quarter. Y.D. More Investments Ltd’s holdings in Brainsway were worth $2,187,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the company. UBS Group AG grew its stake in shares of Brainsway by 2,028.6% during the third quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after buying an additional 60,877 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Brainsway by 25.2% in the third quarter. Two Sigma Investments LP now owns 102,902 shares of the company’s stock worth $1,551,000 after buying an additional 20,706 shares during the period. Millennium Management LLC lifted its stake in shares of Brainsway by 69.6% during the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company’s stock worth $600,000 after acquiring an additional 16,354 shares during the last quarter. Centiva Capital LP purchased a new position in Brainsway during the 3rd quarter valued at $181,000. Finally, Eagle Global Advisors LLC boosted its holdings in Brainsway by 19.3% during the 3rd quarter. Eagle Global Advisors LLC now owns 74,326 shares of the company’s stock valued at $1,120,000 after acquiring an additional 12,000 shares during the period. 30.11% of the stock is currently owned by institutional investors.

Brainsway Price Performance

Shares of NASDAQ BWAY opened at $13.57 on Monday. The stock has a market capitalization of $543.21 million, a P/E ratio of 54.28 and a beta of 1.10. Brainsway Ltd. Sponsored ADR has a 1-year low of $3.92 and a 1-year high of $14.65. The business has a fifty day moving average price of $12.73 and a 200 day moving average price of $10.14.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings data on Wednesday, March 11th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $14.55 million for the quarter, compared to the consensus estimate of $14.02 million. Brainsway had a net margin of 14.62% and a return on equity of 11.10%. As a group, equities research analysts anticipate that Brainsway Ltd. Sponsored ADR will post 0.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Zacks Research raised shares of Brainsway from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Wall Street Zen upgraded shares of Brainsway from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Northland Securities set a $15.00 target price on shares of Brainsway in a research report on Thursday, January 22nd. HC Wainwright decreased their price target on shares of Brainsway from $30.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, March 12th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Brainsway presently has a consensus rating of “Buy” and an average target price of $15.00.

Brainsway Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.